KR20070100878A - 효소 억제제 및 그 용도 - Google Patents

효소 억제제 및 그 용도 Download PDF

Info

Publication number
KR20070100878A
KR20070100878A KR1020077008049A KR20077008049A KR20070100878A KR 20070100878 A KR20070100878 A KR 20070100878A KR 1020077008049 A KR1020077008049 A KR 1020077008049A KR 20077008049 A KR20077008049 A KR 20077008049A KR 20070100878 A KR20070100878 A KR 20070100878A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
aryl
hydrogen
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077008049A
Other languages
English (en)
Korean (ko)
Inventor
시우 인 차이
마이클 윌리엄 파커
안토니 로이드 앨비스톤
크레그 제이 모튼
후이 링 응
시잉 예
프레더릭 에이 오 멘델손
Original Assignee
하워드 플로리 인스티튜트 오브 익스페러멘틀 피지알러지 앤드 메디신
세인트 빈센츠 인스티튜트 오브 메디컬 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by 하워드 플로리 인스티튜트 오브 익스페러멘틀 피지알러지 앤드 메디신, 세인트 빈센츠 인스티튜트 오브 메디컬 리서치 filed Critical 하워드 플로리 인스티튜트 오브 익스페러멘틀 피지알러지 앤드 메디신
Publication of KR20070100878A publication Critical patent/KR20070100878A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
KR1020077008049A 2004-09-09 2005-09-09 효소 억제제 및 그 용도 Withdrawn KR20070100878A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905182 2004-09-09
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20070100878A true KR20070100878A (ko) 2007-10-12

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008049A Withdrawn KR20070100878A (ko) 2004-09-09 2005-09-09 효소 억제제 및 그 용도

Country Status (13)

Country Link
US (1) US20080194636A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789079B1 (cg-RX-API-DMAC7.html)
JP (1) JP5031567B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070100878A (cg-RX-API-DMAC7.html)
CN (1) CN101039690A (cg-RX-API-DMAC7.html)
CA (1) CA2579768A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789079T3 (cg-RX-API-DMAC7.html)
ES (1) ES2403340T3 (cg-RX-API-DMAC7.html)
IL (1) IL181819A (cg-RX-API-DMAC7.html)
NZ (1) NZ553688A (cg-RX-API-DMAC7.html)
SG (1) SG155901A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006026832A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702041B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
PL3150581T3 (pl) 2014-05-28 2020-07-13 Astellas Pharma Inc. Pochodne pirydyny
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
WO2017015720A1 (en) 2015-07-30 2017-02-02 Monash University Fibrotic treatment
WO2023099589A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
US20050020519A1 (en) * 2001-08-02 2005-01-27 Albiston Anthony L. Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
PL372488A1 (en) * 2002-02-13 2005-07-25 F.Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079B1 (en) 2012-11-07
JP5031567B2 (ja) 2012-09-19
US20080194636A1 (en) 2008-08-14
EP1789079A4 (en) 2010-09-01
SG155901A1 (en) 2009-10-29
IL181819A (en) 2013-07-31
JP2008512395A (ja) 2008-04-24
EP1789079A1 (en) 2007-05-30
NZ553688A (en) 2011-05-27
CN101039690A (zh) 2007-09-19
ZA200702041B (en) 2008-09-25
CA2579768A1 (en) 2006-03-16
WO2006026832A1 (en) 2006-03-16
DK1789079T3 (da) 2013-03-11
ES2403340T3 (es) 2013-05-17

Similar Documents

Publication Publication Date Title
AU2007262670B2 (en) Method of treatment of glioma brain tumour
KR102642823B1 (ko) 모발 성장을 조절하기 위한 조성물 및 방법
US8377963B2 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
US20240084308A1 (en) Fibrotic treatment
US7105544B2 (en) Substituted alkyl amido piperidines
JP5031567B2 (ja) 酵素阻害剤およびその使用
JP2022500445A (ja) Gabaa受容体リガンド
US11306066B2 (en) 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
AU2005282229B2 (en) Enzyme inhibitors and uses thereof
JP2022554159A (ja) Gabaa受容体モジュレーターによるてんかん状態の治療
AU2007234577A1 (en) Novel compounds and uses thereof
CA2611072A1 (en) Novel compounds and uses thereof
TW390879B (en) Optionally substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo [4.3.0] nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids having antibacterial activities, their preparation and pharmaceutical composition containing the same
US20060014702A1 (en) Antimicrobial agent
JPH11510159A (ja) 抗けいれん剤としての未置換および置換n−(ピロール−1−イル)ピリジンアミンの使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid